Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: January 2008
-
By Kevin E. Noonan — Craig Venter’s colleagues at the J. Craig Venter Institute show no signs that vocal criticism of their work in synthetic biology has made a dent in their determination to "create life" (see "Playing the Bioterror Card in the Synthetic Biology Debate"). They report in this week’s Science Express…
-
By Donald Zuhn — The U.S. Patent and Trademark Office (USPTO) and the Japan Patent Office (JPO) have announced that the two Offices will begin a new work-sharing pilot program on January 28, 2008. The pilot program, which the Offices are calling the "New Route," will allow each Office to benefit from examinations…
-
By Kevin E. Noonan — As we reported last week, a draft of the Senate Judiciary Committee’s report on the Patent Reform Act of 2007 (S. 1145) has been circulated on the internet. The 106-page draft report contains sections on the background and purpose of the bill, the legislative history of the bill,…
-
By Donald Zuhn — Senomyx, Inc. announced last week that it has been granted five U.S. patents directed to human umami and sweet taste receptors. The patents are U.S. Patent Nos. 7,294,474; 7,297,543; 7,297,772; 7,301,009; and 7,309,577. With the addition of the five new patents, the San Diego-based company, which uses proprietary taste…
-
By Christopher P. Singer — In a Notice signed January 22, 2008, the U.S. Patent and Trademark Office announced that the language of oaths and declarations filed on or after June 1, 2008 will have to comply with the express language of 37 C.F.R. § 1.63. That is, oaths and declarations will need…
-
By Kevin E. Noonan — In the 19th Century, biology was an observational, rather than an experimental, science. Without an understanding of genetics, and with evolution by natural selection being but newly proposed (and in the absence of genetics, not yet accepted), biologists (natural historians, really) spent their time expanding Linnaean systematics, cataloging…
-
By Donald Zuhn — Earlier this month, the Wisconsin Alumni Research Foundation (WARF) announced that it had entered into a licensing agreement with BioTime, Inc. for 173 of WARF’s human embryonic stem cell patents and patent applications (commonly known as the Thomson patents for inventor James Thomson). WARF is a private, non-profit patenting…
-
By Kevin E. Noonan — It appears that rising chorus of naysayers against S. 1145 is larger than we thought. After our post on Friday, Patent Docs has been contacted by two other groups who have organized a letter-writing campaign to Senate leaders beseeching them not to pass S. 1145, the so-called "patent…
-
By Sherri Oslick — As we reported last week, a draft of the Senate Judiciary Committee’s report on the Patent Reform Act of 2007 (S. 1145) has been circulated on the internet. The 106-page draft report contains sections on the background and purpose of the bill, the legislative history of the bill, a…
-
By Donald Zuhn — Roche announced today that it had signed a definitive merger agreement with Ventana Medical Systems. Under the terms of the agreement, Roche will increase its tender offer to $89.50 per share, or approximately $3.4 billion, and Ventana’s Board of Directors will recommend that Ventana’s shareholders tender their shares to…
Patent Docs 